Feature | ACC | February 16, 2023 | Christine Book

Late-breaking Clinical Trials, Featured Clinical Research Sessions Announced for American College of Cardiology ACC.23/WCC

The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions to be presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, La.

The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions to be presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, LA.

The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions being presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, LA.


February 16, 2023 — The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions will be presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, La.

“This is practice-changing science,” said Katie Berlacher, MD, MS, FACC, who is serving as ACC.23 Vice Chair, in referencing the late breaking clinical trials and featured clinical research she discussed during the briefing. Berlacher is an Assistant Professor of Medicine at University of Pittsburgh Medical Center, Program Director – Cardiovascular Fellowship, Associate Chief of Education, and part of the UPMC Heart and Vascular Institute. She is currently serving as chair of the ACC Lifelong Learning Oversight Committee.

There will be a total of five late breaking clinical trial sessions, three of which will be joint sessions with the Journal of American College of Cardiology, the Journal of American Medical Association and the New England Journal of Medicine. Berlacher noted there were 146 submissions for late-breaking clinical trials, equally split between from the United States and from international researchers, of which 43 were accepted. All of sessions will be offered on the Hot Topics Channel, one of six provided to expand availability to attendees, both in-person and remote.

The sessions include:

SATURDAY, MARCH 4

Joint American College of Cardiology/Journal of the American College of Cardiology (JACC) Late-Breaking Clinical Trials (Session 402)
9:30 – 10:30 a.m. CT in Main Tent (Great Hall) 

CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk

TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation

Statins to Prevent the Cardiotoxicity from Anthracyclines: The STOP-CA Trial

 

Featured Clinical Research I (Session 403)
Noon – 1:15 p.m. CT, Room 257 

HALO Trial: Results from a Phase 2, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Uncontrolled Hypertension

Effect of Myocardial Viability, Percutaneous Coronary Intervention and Functional Recovery on Clinical Outcomes in the REVIVED-BCIS2 Randomized Trial

AIMI-HF Trial: Ischemia and Viability Imaging in Heart Failure: The Alternative Imaging Modalities in Ischemic Heart Failure Trial

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: A Multimodality Imaging Study (the Yellow III Study)

On-site Computed Tomography-derived Fractional Flow Reserve to Guide the Management of Patients with Stable Coronary Artery Disease: The TARGET Randomized Trial

SUNDAY, MARCH 5

Joint American College of Cardiology/New England Journal of Medicine (NEJM) Late-Breaking Clinical Trials (Session 405)
8 – 9:15 a.m. CT in Main Tent (Great Hall) 

Minimally Invasive Versus Conventional Sternotomy for Mitral Valve Repair Surgery: An Expertise Based Multicentre Randomised Controlled Trial (UK Mini Mitral)

Transcatheter Edge-to-edge Repair of Functional Mitral Regurgitation in Heart Failure: Final Five-year Results from the COAPT Trial

Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 3-year Outcomes from the Evolut Low Risk Trial

BIOVASC: Complete Revascularization Strategies in Patients Presenting with Acute Coronary Syndromes and Multivessel Coronary Disease

RENOVATE-COMPLEX-PCI: Intravascular Imaging-guided Versus Angiography-guided Procedural Optimization in Complex Percutaneous Coronary Intervention

 

Late-Breaking Clinical Trials III (Session 406)
9:45 – 11 a.m. CT in Main Tent (Great Hall) 

Building Electronic Tools to Enhance and Reinforce CArdiovascular REcommendations For Heart Failure (BETTER CARE-HF): A Pragmatic, Cluster-randomized Trial Comparing Two Ambulatory Clinical Decision Support Tools

A Nationwide Randomized Trial of Electronically Delivered Nudges to Increase Influenza Vaccination Uptake: The NUDGE-FLU Trial

A Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients with Atherosclerotic Cardiovascular Disease (PCDS Statin)

Translating Polygenic Risk for Coronary Artery Disease into Clinically Actionable Information Using Causal A.I.

ACCESS: A Randomized Trial Assessing the Impact of Eliminating Copayment for High Value Preventive Medications for Low-income Seniors with Cardiovascular-related Chronic Diseases

 

Featured Clinical Research II (Session 407)
12:15 – 1:30 p.m. CT in Main Tent (Great Hall) 

RAPID-HF: Atrial Pacing for Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial

Association of a Low-carbohydrate High-fat (Ketogenic) Diet with Plasma Lipid Levels and Cardiovascular Risk in a Population-based Cohort

STREAM-2: Pharmaco-invasive Reperfusion Strategy with Half-dose Tenecteplase in Older St-elevation Myocardial Infarction Patients

Comparison of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-eluting Stents with Ultrathin Struts and Advanced Polymer Technology: The HOST-IDEA Randomized Clinical Trial

Safety and Efficacy of Transcatheter Edge-to-Edge Mitral Repair in Degenerative Mitral Regurgitation: An Analysis of the STS/ACC TVT Registry

 

Late-Breaking Clinical Trials Deep Dive I (Session 408)
2 – 3:15 p.m. CT in Main Tent (Great Hall) 
Additional insights from key clinical trials presented will be discussed.

 

Clinical and Investigative Horizons (Session 414)
2 – 3:15 p.m. CT (Room 338)

Prediction of Preeclampsia Using High-Sensitivity Troponin I

Outcomes in High-risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy: Results from The FLAME Study

Health 360x Registry: Equitable Access to Point of Care Decentralized Clinical Trials

Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic Val122ile Variant

Impact Of Remote Cardiac Device Monitoring on Green House Emissions: Data from the Global Cardiovascular Carbon Footprint (GCCF) Project

MONDAY, MARCH 6

Joint American College of Cardiology/Journal of the American Medical Association (JAMA) Late-Breaking Clinical Trials (Session 409)
8:30 – 9:45 a.m. CT in Main Tent (Great Hall) 

PULSED Field Ablation Treatment in Paroxysmal and Persistent Atrial Fibrillation Patients: Acute and Long-term Outcomes from the PULSED AF Pivotal Trial

Impact of Heart Failure Management Using Thoracic Fluid Monitoring from a Novel Wearable Sensor: Results of the Benefits of Microcor (μCor) in Ambulatory Decompensated Heart Failure (BMAD) Trial

A Novel Breakthrough in Wrist-Worn Transdermal Troponin-I-Sensor Assessment for Acute Myocardial Infarction

Efficacy and Safety of Macitentan Tadalafil Fixed Dose Combination in Pulmonary Arterial Hypertension: Results from the Randomized Controlled Phase III A DUE Study

Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes (COORDINATE Diabetes): Primary Results

 

Late-Breaking Clinical Trials V (Session 410)
11 a.m. – 12:15 p.m. CT in Main Tent (Great Hall) 

Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy (HCM): Primary Results of the Prospective, Multinational Lifestyle and Exercise in HCM (LIVE-HCM) Study

Return-to-Play for Elite Level Athletes with Sudden Cardiac Death Predisposing Genetic Heart Diseases

Anticoagulation Strategies in Non-critically Ill Hospitalized Covid-19 Patients: Principal Outcomes of the Freedom Covid Anticoagulation Trial

The STELLAR Phase III Trial: A Study of Sotatercept in Combination with Background Therapy For the Treatment of Pulmonary Arterial Hypertension

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

 

Featured Clinical Research III (Session 411)
12:45 – 2 p.m. CT in La Nouvelle B 

Masters@Heart: Lifelong Endurance Exercise and Its Relationship with Coronary Atherosclerosis

Residual Inflammatory Risk in Contemporary Statin Treated Patients: A Collaborative Analyses Of 31,197 Participants in the PROMINENT, REDUCE-IT, and STRENGTH Trials

The LOADSTAR Trial: Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy in Patients with Coronary Artery Disease

CAMEO-DAPA Trial: Evaluation of the Mechanism of Benefit for Dapagliflozin in Heart Failure with Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial

Safety and Efficacy of Virtual Care Team Guided Therapeutic Optimization During Hospitalization in Patients with HFrEF: The IMPLEMENT-HF Study

 

Late-Breaking Clinical Trials Deep Dive II (Session 413)
2:30 – 3:45 p.m. CT in La Nouvelle B 

Additional insights from key clinical trials presented will be discussed.

“We really feel that this has been an outstanding year for science at ACC 23 WCC,” said Douglas Drachman, MD, FACC, Chair of the 2023 ACC Scientific Session during his program overview. Drachman is the Director of Education at the Corrigan Minehan Heart Center, and the Teresa G. and Ferdinand F. Martignetti Endowed Chair for Cardiovascular Medicine at Massachusetts General Hospital. He joined ACC staff and ACC.23 Vice Chair Katie Berlacher, MD, MS, FACC to provide a media briefing detailing the broad range of educational and scientific sessions and interactive opportunities scheduled to support cardiologists throughout the 3-day meeting.

For more information:

https://accscientificsession.acc.org

https://accscientificsession.acc.org/en/Plan-Your-Program

Related content:

American College of Cardiology Announces “ACC.23 Together with WCC” Program Highlights

ACC 2023 Late-breaking Clinical Trials Announced

Find more news from ACC


Related Content

News | Cardiovascular Education

May 31, 2024 — In the United States there are over 8 million active athletes. Given the rapid expansion of sports ...

Home May 31, 2024
Home
News | Cardiovascular Education

April 25, 2024 —Heart-Valve-Surgery.com, a leading patient advocacy group for heart valve disease, with support from ...

Home April 25, 2024
Home
News | Cardiovascular Education

March 21, 2024 — The UCLA Department of Medicine has announced that Priscilla Hsue, MD will be joining as the chief of ...

Home March 21, 2024
Home
Feature | Cardiovascular Education | Christine Book

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country ...

Home February 01, 2024
Home
News | Cardiovascular Education

January 15, 2024 — A public-private partnership Think Tank, scheduled for Feb. 29-March 1, will be presented by the ...

Home January 15, 2024
Home
News | Cardiovascular Education

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

Home December 04, 2023
Home
News | Cardiovascular Education

October 5, 2023 — The 2023 American College of Cardiology (ACC) Quality Summit kicks off on October 11-13 in Orlando ...

Home October 05, 2023
Home
News | Cardiovascular Education

DAIC’s award-winning editorial team delivers industry trends and technology information to the professionals who make ...

Home August 16, 2023
Home
Feature | Cardiovascular Education | Christine Book

May 4, 2023 — A new book on a broad collection of cases, led by a team of investigators from the Smidt Heart Institute ...

Home May 04, 2023
Home
News | Cardiovascular Education

April 10, 2023 — Viatris Inc., a global healthcare company, and the American College of Cardiology (ACC) today released ...

Home April 10, 2023
Home
Subscribe Now